MediView Secures $24M to Revolutionize Surgery with Augmented Reality
October 7, 2025, 3:36 pm
Location: United States, Ohio, Cleveland
Employees: 10001+
Founded date: 1921
Total raised: $24.22M
Location: United States, Minnesota, Rochester
Employees: 10001+
Founded date: 1978
Total raised: $1.38B
MediView XR secured $24M Series A funding, led by GE HealthCare. Cleveland Clinic, Mayo Clinic, and other strategic investors backed the round. The capital propels expansion of MediView's FDA-cleared OmnifyXR platform. This augmented reality solution grants clinicians "X-ray vision." It overlays real-time 3D patient anatomy directly onto the body. This innovation simplifies biopsies, tumor ablations, and injections. It boosts precision, reduces cognitive burden, and enhances procedural efficiency. The technology transforms minimally invasive interventions, setting a new standard for advanced visualization and guided care.
MediView XR has achieved a significant milestone in medical innovation. The company secured a substantial $24 million in Series A funding. This capital injection is set to accelerate the deployment of its groundbreaking surgical navigation platform. The investment round was spearheaded by GE HealthCare, a global leader in medical technology. This partnership alone signifies strong industry validation for MediView’s vision.
Other major players quickly joined the funding syndicate. Cleveland Clinic, Mayo Clinic, Edge Ventures, Emplify Health, and JobsOhio Growth Capital Fund all participated. These powerful institutional commitments underscore widespread confidence in MediView’s mission. Healthcare leaders recognize the profound, transformative potential of this technology. It promises to reshape interventional medicine.
MediView’s core offering is the OmnifyXR Interventional Suite. This system is an FDA-cleared platform. It leverages augmented reality (AR) to provide clinicians with unparalleled visualization capabilities. The technology effectively empowers medical professionals with "X-ray vision." They can now see a patient’s internal anatomy in full 3D context. This dynamic 3D view overlays directly onto the patient's body in real-time.
Traditional medical imaging presents significant operational challenges. Physicians typically translate complex 2D images from screens into mental 3D maps. This process creates a substantial cognitive strain. It often disrupts natural hand-eye coordination during delicate procedures. MediView’s technology directly addresses and eliminates this longstanding burden. It precisely fuses 3D CT scans with live ultrasound data. This generates real-time, interactive 3D visualizations. Internal organs, soft tissue, complex vasculature, and critical target anatomies like tumors become instantly visible.
This head-up, hands-free 3D experience is a revolutionary advancement. Proceduralists gain an immediate, direct sight of internal structures. They target inconspicuous lesions with unprecedented accuracy. Cognitive load on the clinician decreases significantly. Overall workflow efficiency improves dramatically. Precision remains consistently high, even during the most challenging interventions. Procedures such as biopsies, tumor ablations, and targeted injections become more predictable and controllable.
The technology’s impact extends beyond individual procedures. It fundamentally simplifies complex medical interventions. This simplification expands access to less invasive care options for patients nationwide. Such advancements mean better outcomes for a broader patient population. It truly shifts the paradigm of interventional medicine. Remote collaboration also becomes an accessible reality. Colleagues can share real-time visualizations. They offer expert guidance from any location, enhancing team capabilities.
The $24 million funding fuels MediView’s ambitious expansion plans. The company aims to broaden both clinical and commercial adoption of OmnifyXR. Strategic partnerships with leading imaging and medical device companies will deepen. Further scientific validation through rigorous clinical studies is paramount. Necessary regulatory approvals will continue to be pursued. Operational capacity must significantly expand to meet projected rising demand. The platform itself will extend its utility to new and diverse clinical specialties.
MediView’s innovation aligns perfectly with a broader, accelerating trend in healthcare. Augmented reality and artificial intelligence are rapidly converging. This convergence streamlines surgical workflows like never before. Mundane tasks, such as complex image processing, automate seamlessly. Real-time data insights integrate directly into the procedural environment. MediView positions itself at the absolute forefront of this technological transformation. The company offers a truly new standard for interventional care. This standard combines advanced visualization with intuitive, precise guidance.
The mission is crystal clear. MediView seeks to simplify, democratize, and inform medical procedures globally. Clinicians receive intuitive, real-time 3D visualization and guidance tools. These tools directly aid critical clinical decision-making. The understanding and navigation of interventional tools fundamentally improve. The complex relationship between instruments and target anatomy clarifies instantly. Less invasive procedures become significantly more predictable. They also become dramatically more accessible to a wider patient base. This enhances outcomes and strengthens patient safety. It collectively establishes a powerful new benchmark in interventional medicine.
GE HealthCare's leadership in this significant funding round is noteworthy. It highlights the strategic importance of augmented reality in modern medical imaging. GE HealthCare actively seeks to integrate advanced imaging capabilities. They aim for intuitive AR technologies that possess the potential to transform precision care. Redefining how clinicians visualize anatomy in real-time is a key objective. This ultimately enhances procedural guidance and precise navigation. MediView is decisively leading this crucial charge.
MediView XR is actively reshaping the landscape of surgical navigation. Its innovative augmented reality platform delivers true "X-ray vision" directly to clinicians. The recent infusion of $24 million in funding propels its mission forward. It makes inherently complex medical procedures simpler, safer, and more precise. This investment accelerates a new era in precision medicine. MediView is not just participating; it is actively setting a powerful new standard for interventional care globally.
MediView XR has achieved a significant milestone in medical innovation. The company secured a substantial $24 million in Series A funding. This capital injection is set to accelerate the deployment of its groundbreaking surgical navigation platform. The investment round was spearheaded by GE HealthCare, a global leader in medical technology. This partnership alone signifies strong industry validation for MediView’s vision.
Other major players quickly joined the funding syndicate. Cleveland Clinic, Mayo Clinic, Edge Ventures, Emplify Health, and JobsOhio Growth Capital Fund all participated. These powerful institutional commitments underscore widespread confidence in MediView’s mission. Healthcare leaders recognize the profound, transformative potential of this technology. It promises to reshape interventional medicine.
MediView’s core offering is the OmnifyXR Interventional Suite. This system is an FDA-cleared platform. It leverages augmented reality (AR) to provide clinicians with unparalleled visualization capabilities. The technology effectively empowers medical professionals with "X-ray vision." They can now see a patient’s internal anatomy in full 3D context. This dynamic 3D view overlays directly onto the patient's body in real-time.
Traditional medical imaging presents significant operational challenges. Physicians typically translate complex 2D images from screens into mental 3D maps. This process creates a substantial cognitive strain. It often disrupts natural hand-eye coordination during delicate procedures. MediView’s technology directly addresses and eliminates this longstanding burden. It precisely fuses 3D CT scans with live ultrasound data. This generates real-time, interactive 3D visualizations. Internal organs, soft tissue, complex vasculature, and critical target anatomies like tumors become instantly visible.
This head-up, hands-free 3D experience is a revolutionary advancement. Proceduralists gain an immediate, direct sight of internal structures. They target inconspicuous lesions with unprecedented accuracy. Cognitive load on the clinician decreases significantly. Overall workflow efficiency improves dramatically. Precision remains consistently high, even during the most challenging interventions. Procedures such as biopsies, tumor ablations, and targeted injections become more predictable and controllable.
The technology’s impact extends beyond individual procedures. It fundamentally simplifies complex medical interventions. This simplification expands access to less invasive care options for patients nationwide. Such advancements mean better outcomes for a broader patient population. It truly shifts the paradigm of interventional medicine. Remote collaboration also becomes an accessible reality. Colleagues can share real-time visualizations. They offer expert guidance from any location, enhancing team capabilities.
The $24 million funding fuels MediView’s ambitious expansion plans. The company aims to broaden both clinical and commercial adoption of OmnifyXR. Strategic partnerships with leading imaging and medical device companies will deepen. Further scientific validation through rigorous clinical studies is paramount. Necessary regulatory approvals will continue to be pursued. Operational capacity must significantly expand to meet projected rising demand. The platform itself will extend its utility to new and diverse clinical specialties.
MediView’s innovation aligns perfectly with a broader, accelerating trend in healthcare. Augmented reality and artificial intelligence are rapidly converging. This convergence streamlines surgical workflows like never before. Mundane tasks, such as complex image processing, automate seamlessly. Real-time data insights integrate directly into the procedural environment. MediView positions itself at the absolute forefront of this technological transformation. The company offers a truly new standard for interventional care. This standard combines advanced visualization with intuitive, precise guidance.
The mission is crystal clear. MediView seeks to simplify, democratize, and inform medical procedures globally. Clinicians receive intuitive, real-time 3D visualization and guidance tools. These tools directly aid critical clinical decision-making. The understanding and navigation of interventional tools fundamentally improve. The complex relationship between instruments and target anatomy clarifies instantly. Less invasive procedures become significantly more predictable. They also become dramatically more accessible to a wider patient base. This enhances outcomes and strengthens patient safety. It collectively establishes a powerful new benchmark in interventional medicine.
GE HealthCare's leadership in this significant funding round is noteworthy. It highlights the strategic importance of augmented reality in modern medical imaging. GE HealthCare actively seeks to integrate advanced imaging capabilities. They aim for intuitive AR technologies that possess the potential to transform precision care. Redefining how clinicians visualize anatomy in real-time is a key objective. This ultimately enhances procedural guidance and precise navigation. MediView is decisively leading this crucial charge.
MediView XR is actively reshaping the landscape of surgical navigation. Its innovative augmented reality platform delivers true "X-ray vision" directly to clinicians. The recent infusion of $24 million in funding propels its mission forward. It makes inherently complex medical procedures simpler, safer, and more precise. This investment accelerates a new era in precision medicine. MediView is not just participating; it is actively setting a powerful new standard for interventional care globally.